Evaluation of Bivalirudin as the Primary Anticoagulant in Patients Receiving Extracorporeal Membrane Oxygenation for SARS-CoV-2-Associated Acute Respiratory Failure.
Brittany D BissellTaylor GabbardErica A SheridanMaher A BazGeorge A DavisAyesha AtherPublished in: The Annals of pharmacotherapy (2021)
In the first published report of its use within this population, bivalirudin was found to be a viable choice for anticoagulation in those patients on ECMO for severe respiratory failure secondary to COVID-19.
Keyphrases
- respiratory failure
- extracorporeal membrane oxygenation
- sars cov
- acute respiratory distress syndrome
- mechanical ventilation
- end stage renal disease
- atrial fibrillation
- venous thromboembolism
- percutaneous coronary intervention
- coronavirus disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- respiratory syndrome coronavirus
- systematic review
- intensive care unit
- decision making
- coronary artery disease
- drug induced